Glycine and hyperammonemia : potential target for the treatment of hepatic encephalopathy by Kristiansen, Rune et al.
This is a post-peer-review, pre-copyedit version of an article published in Metabolic Brain Disease. The final 
authenticated version is available online at: http://dx.doi.org/10.1007/s11011-016-9858-2 
Kristiansen R G, Rose C F, Ytrebø L M. Glycine and hyperammonemia: potential target for the treatment of 
hepatic encephalopathy. Metab Brain Dis. 2016-06;31(6):1269–1273. Available at: 
http://dx.doi.org/10.1007/s11011-016-9858-2 
GLYCINE AND HYPERAMMONEMIA: POTENTIAL 




, Christopher F. Rose
3




1. Department of Anesthesiology, Anesthesia and Critical Care Research Group, University 
Hospital of North Norway and UiT-The Arctic University of Norway, Tromsø, Norway 
2. Department of Anesthesiology, Ålesund Hospital, Helse Møre og Romsdal, 6010, Ålesund, 
Norway 
3. Hepato-Neuro Laboratory, CRCHUM, Université de Montréal, Montréal, QC, Canada 
KEYWORDS 
Ammonia; Glutamine; Glycine; L-ornithine-phenylacetate (OP); Phenylacetylglycine 
ABBREVIATIONS 
HE:Hepatic encephalopathy ; GCS:Glycine cleavage system;  OP: L-ornithine Phenylacetate;  GS:; Glutamine synthetase; 
GDH:Glutamate dehydrogenase; ALF:Acute liver failure; NMDA receptor:N-methyl–D-aspartate; NKH:Non-ketotic 
hyperglycinemia 
ABSTRACT 
Hepatic encephalopathy (HE) is a neuropsychiatric disorder caused by hepatic dysfunction. Numerous 
studies dictate that ammonia plays an important role in the pathogenesis of HE, and hyperammonemia 
can lead to alterations in amino acid homeostasis. Glutamine and glycine are both ammoniagenic 
amino acids that are increased in liver failure. Modulating the levels of glutamine and glycine has 
shown to reduce ammonia concentration in hyperammonemia. Ornithine Phenylacetate (OP) has 
consistently been shown to reduce arterial ammonia levels in liver failure by modulating glutamine 
levels. In addition to this, OP has also been found to modulate glycine concentration providing an 
additional ammonia removing effect. Data support that glycine also serves an important role in N-
methyl D-aspartate (NMDA) receptor mediated neurotransmission in HE. This potential important role 
for glycine in the pathogenesis of HE merits further investigations. 
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HEPATIC ENCEPHALOPATHY 
Hepatic encephalopathy (HE) is a neuropsychiatric disorder caused by hepatic failure. It covers a wide 
spectrum of symptoms ranging from mild cognitive deficits to coma (Vilstrup et al. 2014). Liver failure 
leads to impairment of the urea cycle which consequently affects nitrogen handling and 
hyperammonemia develops. Numerous studies in animal models and patients dictate that ammonia 
plays an important role in the pathogenesis of HE (Clemmesen et al. 1999; Ong et al. 2003; Bernal et 
al. 2007). Therefore, developing treatments for reducing blood ammonia levels in patients suffering 
from liver disease remains a primary therapeutic strategy in HE (Rose 2012). 
Hyperammonemia leads to alterations in amino acid homeostasis. Glutamine and glycine are of 
particular interest in this context as they have been shown to be significantly increased in blood in both 
humans and animal models of liver failure (Record et al. 1976; Clemmesen et al. 2000; Strauss et al. 
2001). Furthermore, altered amino acid balance has been found in the brain and considered to be 
implicated in the pathogenesis of HE (Swain et al. 1992; Mans et al. 1994) possibly impairing 
neurotransmission and brain function (Swain et al. 1992). 
GLUTAMINE 
Glutamine is the most abundant free amino acid in the body. Synthesis of glutamine (through the 
amidation of glutamate) by glutamine synthetase (GS) has been targeted as an important alternative 
pathway in clearing ammonia, particularly in the muscle (Desjardins et al. 1999; Rose et al. 1999). 
GS is also expressed in the brain, specifically in astrocytes. Under physiological conditions, GS plays 
an important role in the glutamate-glutamine shuttle as glutamine generated via GS in the astrocyte is 
shuttled to the neuron where it is converted to glutamate through glutaminase, replenishing the 
glutamate neurotransmitter pool in the neuron. Released glutamate from the neuron is then taken up by 
the astrocytes and used to subsequently generate glutamine (Martinez-Hernandez et al. 1977; 
Schousboe et al. 1977; Suarez et al. 2002). 
During hyperammonemia with subsequent elevated levels of ammonia in the brain, GS becomes the 
sole ammonia removing pathway and it is believed that glutamine accumulation within the astrocytes 
leads to astrocyte swelling and consequently brain edema (Butterworth 2014). Furthermore, elevated 
glutamine levels can interfere with glutamatergic neurotransmission via the N-methyl-D-aspartate 
(NMDA) receptor, contributing to the development of HE (Ott and Vilstrup 2014). 
During liver disease, GS expression and activity in skeletal muscles are upregulated and therefore has 
become a potential target for lowering blood ammonia levels (Desjardins et al. 1999). L-Ornithine L-
Aspartate has been shown to be effective in lowering blood ammonia, possibly by increasing glutamine 
production via GS in muscle (Rose et al. 1999). However, concerns have been raised regarding a 
potential ammonia rebound effect as glutamine can be metabolized via glutaminase (located in 
intestines and kidneys) and thus regenerate ammonia. Therefore, glutaminase activity (ammonia 
generation) limits maximum ammonia removal potential via GS (Jalan and Lee 2009). 
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Studies have also shown a beneficial effect on lowering blood ammonia and HE events by 
administering the glutamine scavenger phenylacetate (as glycerol phenylbutyrate, pro-drug for 
phenylacetate) (McGuire et al. 2010; Rockey et al. 2014). 
However, stimulating GS as well as removing the newly synthesized glutamine has been proposed as 
an efficient novel therapeutic ammonia-lowering strategy. Jalan et al. recently proposed Ornithine 
Phenylacetate (OP) as a novel concept to maximize ammonia clearance during liver disease. This 
involves stimulating ammonia removal via GS with ornithine in skeletal muscle and chelating 
glutamine with phenylacetate to form phenylacetylglutamine which is easily excreted in the urine 
(Jalan et al. 2007). 
GLYCINE 
Glycine is a conditionally essential, one carbon amino acid. It can be synthesized from serine, threonine 
and choline, and via transamination with alanine from glyoxylate (Wang et al. 2013). Glycine is 
metabolized by the glycine cleavage system (GCS) and glycine oxidase (Fig. 1). 
GCS is a multi enzyme complex and found to be active in liver, kidney, brain and testis. In the brain 
GCS is confined to astrocytes (Sato et al. 1991). 
 
 
Fig. 1 The glycine pathways in relation to Ornithine Phenylacetate. Glycine can be synthesized from serine, threonine and 
choline, and via transamination with alanine from glyoxylate. The main catabolic pathway is the glycine cleavage system 
(GCS). Hyperammonemia modulates GDH reaction in favor of glutamate production. Glutamate acts as amino group donor 
in the synthesis of serine, driving glutamate production from α-ketoglutarate removing ammonia. Serine can further be 
metabolized to glycine. GDH; glutamate dehydrogenase reaction 
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GLYCINE AND AMMONIA 
Like glutamine, glycine can also be an active ammoniagenic amino acid leading to changes in both 
plasma and brain ammonia levels. Rudman et al. studied the ammonia liberating potential of different 
amino acids in patients with liver failure, and glycine was found to be important in liberating ammonia 
(Rudman et al. 1973). In accordance with this, we found that cirrhotic rats injected with glycine 
intraperitoneally (IP) leads to an increase in blood ammonia (Rose, unpublished data). Rudman et al. 
concluded that ammonia was released through the glycine oxidase reaction directly deaminating 
glycine (Kikuchi 1973; Rudman et al. 1973). However, the main catabolic pathway for glycine is 
considered to be through the GCS, liberating ammonia (Van Hove et al. 2005). 
Studies have shown an ammonia modulating effect by the administration of the glycine scavenger 
sodium benzoate to liver failure patients (Sushma et al. 1992; Misel et al. 2013). Sushma et al. found 
that administration of benzoate to patients with cirrhotic liver failure attenuated ammonia levels, and 
outcome was found to be as good as with lactulose treatment (Sushma et al. 1992). Furthermore, 
combined treatment with benzoate and phenylacetate reduces ammonia levels, mortality and morbidity 
in children with urea cycle disorders (Enns et al. 2007), and has shown beneficial effects in patients 
with portal systemic encephalopathy (Mendenhall et al. 1986). 
GLYCINE AND THE NMDA-RECEPTOR 
Glycine is implicated in excitatory neurotransmission as a positive modulator on the NMDA-receptor 
in the cerebral cortex, cerebellum and hippocampus (Sakata et al. 2001). The NMDA-receptor is 
located on the postsynaptic neuronal membrane and is part of the glutamatergic neurotransmission 
system (Vaquero and Butterworth 2006). 
Inherited defects in the GCS, known as non-ketotic hyperglycinemia (NKH), results in increased 
glycine in the cerebrospinal fluid leading to encephalopathy, possibly as a result of increased activation 
of NMDA receptors in the frontal cortex (Tada and Kure 1993). The role of ammonia in NKH has not 
been evaluated. Reducing glycine level in plasma and CSF with benzoate, combined with the NMDA-
antagonist dextromethorphan was found to improve outcome for some patients with NKH (Hamosh et 
al. 1998). 
In the setting of liver failure, evidence has emerged suggesting that alterations in the glutamate system 
are involved in the pathogenesis of HE (Butterworth 1997). An increased extracellular concentration of 
glutamate, possibly due to decreased trafficking of glutamate between astrocytes and neurons, has been 
observed in ALF animals with a positive correlation with severity of HE and arterial ammonia levels 
(Michalak et al. 1996). Increased glutamate can lead to increased NMDA receptor activity. In support 
for this, studies have shown that inhibitors of NMDA-receptors (memantine) can improve the clinical 
grade of HE in animals with ALF (Vogels et al. 1997). 
In a porcine model of acute liver failure (ALF) we found significantly increased levels of both arterial 
and brain glycine compared to sham operated animals (Kristiansen et al. 2014). Increased extracellular 
level of glycine in the brain has also been found in several other animal models of liver failure 
(Bosman et al. 1992; Swain et al. 1992; Michalak et al. 1996). Zwingmann et al. found that increased 
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brain extracellular glycine was a result of decreased uptake by Glyt-1 transporters in the brain of rats 
with ALF (Zwingmann et al. 2002). A potential role for glycine as a positive modulator of the NMDA-
receptor in HE merits further investigations. 
ORNITHINE PHENYLACETATE; MAXIMIZING AMMONIA REMOVAL? 
During liver disease, it has been shown that increasing the synthesis of glutamine (via GS), leads to a 
reduction in blood ammonia (Rose et al. 1999). Furthermore, removing glutamine and glycine by the 
administration of phenylacetate and benzoate respectively, has been shown to reduce ammonia levels in 
patients with urea cycle disorders (Enns et al. 2007) and patients with HE (Rockey et al. 2014). 
Ornithine Phenylacetate (OP) targets both glutamine production and removal. Ornithine increases the 
provision of glutamate in order to stimulate GS and generate glutamine and remove ammonia. 
Phenylacetate conjugates with the newly formed glutamine to form phenylacetylglutamine which 
cannot be metabolized by glutaminase and thus prevents an ammonia rebound effect (Jalan et al. 2007). 
OP has consistently been shown to decrease arterial ammonia levels both in humans and in several 
animal models of both acute and chronic liver failure (Ytrebo et al. 2009; Davies et al. 2009; 
Balasubramaniyan et al. 2012; Oria et al. 2012; Wright et al. 2012; Dadsetan et al. 2013; Ventura-Cots 
et al. 2013; Jover-Cobos et al. 2014). We have previously shown a significant reduction in arterial 
ammonia by OP treatment in a porcine model of ALF (Ytrebo et al. 2009). 
However, in numerous studies (including ours) the excretion of PAGN did not correlate with the 
decrease in arterial ammonia. Furthermore, a study in cirrhotic patients suffering from upper 
gastrointestinal bleed found a recovery rate of phenylacetate as PAGN of only 31.9 % over 5 days 
(Ventura-Cots et al. 2013). Two studies of bile duct ligated (BDL) rats reported a lack of correlation 
between ammonia reduction and PAGN excretion explained by kinetics of PAGN excretion and 
additional pathways for PAGN metabolism in animal models compared to humans (Davies et al. 2009; 
Dadsetan et al. 2013; Jover-Cobos et al. 2013). This led us to investigate whether alternative pathways 
could be involved, and interestingly enough we were able to show a significant correlation between 
arterial ammonia and glycine levels (Kristiansen et al. 2014). 
This increase in glycine and removal of ammonia might have been mediated through the glutamate 
dehydrogenase (GDH) (Brusilow et al. 1980) reaction in the kidneys. Hyperammonemia modulates 
GDH reaction in favor of glutamate production (Cooper and Plum 1987). Glutamate acts as amino 
group donor in the synthesis of serine, driving glutamate production from α-ketoglutarate removing 
ammonia. Serine can further be metabolized to glycine. However, glycine can also be synthesized from 
glyoxylate, using alanine as amino group donor, or possibly through the reversible glycine cleavage 
system (Kristiansen et al. 2014) (Fig. 1). 
Interestingly, using a porcine model of ALF we found a positive correlation between brain glycine and 
intracranial pressure (Kristiansen et al. 2014). However, the mechanism for this observation remains to 
be studied. 
Benzoate and phenylacetate conjugates with glycine and glutamine respectively, and are excreted as 
hippuric acid and phenylacetylglutamine. This leads to a net ammonia removal in urine and prevents 
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glutamine and glycine from being re-metabolized to ammonia. Furthermore, the replenishment of 
glycine and glutamine stores can remove ammonia through GS and GDH reactions (Kristiansen et al. 
2014). 
In our study we found phenylacetate to conjugate with glutamine as well as glycine as a highly 
significant increase in excretion of phenylacetylglycine was found in the OP treated animals compared 
to placebo treated animals (Kristiansen et al. 2014). This was accompanied by a significant attenuation 
of glycine which correlated with the attenuation of ammonia. Moreover, our data suggest that the 
conjugation between glycine and phenylacetate takes place in the kidneys. 
In conclusion, glycine is an ammoniagenic amino acid as well as a positive modulator of NMDA 
receptors in the brain. Lowering glycine levels has demonstrated to be beneficial in lowering ammonia 
and well as resolving encephalopathy. Therefore, targeting glycine for the treatment of HE merits to be 
further investigated. 
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